8-K current report · filed Jul 28, 2026

Incyte (INCY) 8-K Current Report: July 28, 2026

Item 2.02Item EX-99.1INCY overview

Short answer

Incyte (INCY) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results covered quarter ended June 30, 2026.

Incyte 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 fiscal 2026 results covered quarter ended June 30, 2026
  • Press release furnished as Exhibit 99.1, containing the detailed financial results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $1.67B, up 38%, with GAAP net income $586M and diluted EPS $2.81
  • Opzelura sales $450M, up 173%, including a $246M one-time CMS-related non-cash benefit
  • Underlying Opzelura sales $204M, up 24%, signaling commercial growth beyond the accounting benefit
  • 2026 sales guidance raised to $5.13B-$5.26B, while expense guidance rises for Vega acquisition costs
  • Vega acquired for $1.25B, adding Phase 3 latarcibart and potential milestone payments up to $750M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Incyte 8-K filings

Get the next INCY 8-K as it lands

Follow INCY for push alerts, or ask the research agent what this filing means.